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Dear Editor,
We sincerely thank Viscido et al. (1) for their appropriate and 
sharable comments on our recent study on adalimumab 
biosimilar ABP 501 in Crohn’s disease (CD) (2). The use of a 
biosimilar in inflammatory disorders is one of the current 
main topics, given the great opportunity to save resources 
that can be invested in innovative drugs and the ethical 
problems that non-medical switching can generate (3).
We completely agree with Viscido et al. (1) that the process 
of authorization of biosimilars by regulatory agencies is 
highly regulated (4). However, we would like to underline 
the fact that the use of biosimilar of adalimumab in CD is 
now widespread in the clinical practice, without random-
ized controlled trials in CD (for example for ABP 501). This 
is a noteworthy fact, that the concept of extrapolation is 
unique to biosimilars.
Like Viscido et al. (1), we conclude that the use of biosimi-
lars approved by regulatory agencies is desirable in both 
naive and experienced patients. However, we would also 
like to underline that studies about their efficacy and safety 
in inflammatory bowel diseases are equally desirable. Final-
ly, the doctor must be the last decision maker about the 
therapy in the patient, whilst taking into account a conscien-
tious use of resources. For example, patients with unstable 
disease in which a change of therapy is expected should 
maintain the drug currently in use.
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